Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Vivos Therapeutics (VVOS) Gross Profit (2020 - 2025)

Vivos Therapeutics (VVOS) has disclosed Gross Profit for 6 consecutive years, with $3.9 million as the latest value for Q3 2025.

  • On a quarterly basis, Gross Profit rose 68.59% to $3.9 million in Q3 2025 year-over-year; TTM through Sep 2025 was $9.7 million, a 7.1% increase, with the full-year FY2024 number at $9.0 million, up 9.04% from a year prior.
  • Gross Profit was $3.9 million for Q3 2025 at Vivos Therapeutics, up from $2.1 million in the prior quarter.
  • In the past five years, Gross Profit ranged from a high of $3.9 million in Q3 2025 to a low of $1.5 million in Q1 2025.
  • A 5-year average of $2.5 million and a median of $2.4 million in 2022 define the central range for Gross Profit.
  • Peak YoY movement for Gross Profit: tumbled 30.05% in 2023, then skyrocketed 68.59% in 2025.
  • Vivos Therapeutics' Gross Profit stood at $3.1 million in 2021, then decreased by 23.27% to $2.4 million in 2022, then decreased by 12.37% to $2.1 million in 2023, then rose by 0.38% to $2.1 million in 2024, then skyrocketed by 87.65% to $3.9 million in 2025.
  • Per Business Quant, the three most recent readings for VVOS's Gross Profit are $3.9 million (Q3 2025), $2.1 million (Q2 2025), and $1.5 million (Q1 2025).